These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 2958829)

  • 1. [Parkinson's disease 20 years later].
    Guillard A
    Presse Med; 1987 Oct; 16(32):1565-6. PubMed ID: 2958829
    [No Abstract]   [Full Text] [Related]  

  • 2. [Striatal dopamine availability in Parkinson's disease--with reference to the wearing-off phenomenon].
    Indo T
    Rinsho Shinkeigaku; 1984 Oct; 24(10):1008-16. PubMed ID: 6518691
    [No Abstract]   [Full Text] [Related]  

  • 3. Dopamine receptors in Parkinson's disease.
    Hassan MN; Thakar JH
    Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(2-3):173-82. PubMed ID: 3290993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levodopa therapy in Parkinson's disease.
    Koller WC; Hubble JP
    Neurology; 1990 Oct; 40(10 Suppl 3):suppl 40-7; discussion 47-9. PubMed ID: 2215973
    [No Abstract]   [Full Text] [Related]  

  • 5. Parkinson's disease and its chemotherapy.
    Hornykiewicz O
    Biochem Pharmacol; 1975 May; 24(10):1061-5. PubMed ID: 239718
    [No Abstract]   [Full Text] [Related]  

  • 6. Study on the striatal dopamine availability in Parkinson's disease.
    Indo T
    Jpn J Med; 1984 Aug; 23(3):228-36. PubMed ID: 6492486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping neuronal activity of the basal ganglia in experimental models of Parkinson's disease: contributions of the [14C]2-deoxyglucose method.
    Orzi F; Fornai F; Blandini F
    Funct Neurol; 2000; 15(4):269-76. PubMed ID: 11213530
    [No Abstract]   [Full Text] [Related]  

  • 8. [Dopamine agonists in the therapy of parkinson syndrome].
    Kapfhammer HP; Rüther E
    Nervenarzt; 1985 Feb; 56(2):69-81. PubMed ID: 3982566
    [No Abstract]   [Full Text] [Related]  

  • 9. Fluctuations in response to L-dopa in Parkinson's disease may be explained by changes in striatal dopamine turnover.
    Rose S; Thomas K; Jenner P; Marsden CD
    Br J Pharmacol; 1989 Dec; 98 Suppl():816P. PubMed ID: 2611523
    [No Abstract]   [Full Text] [Related]  

  • 10. Levodopa and the progression of Parkinson's disease.
    Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
    N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glutamate measurement in Parkinson's disease using MRS at 3 T field strength.
    Kickler N; Krack P; Fraix V; Lebas JF; Lamalle L; Durif F; Krainik A; Rémy C; Segebarth C; Pollak P
    NMR Biomed; 2007 Dec; 20(8):757-62. PubMed ID: 17334978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease.
    Di Rocco A; Werner P
    Ann Neurol; 2000 Jan; 47(1):136-7. PubMed ID: 10632116
    [No Abstract]   [Full Text] [Related]  

  • 13. [Parkinson's disease and neurotransmitters].
    Narabayashi H
    Nihon Rinsho; 1984 Apr; 42(4):869-74. PubMed ID: 6481982
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of dopaminergic treatment on striatal dopamine turnover in de novo Parkinson disease.
    Storch A; Wolz M; Beuthien-Baumann B; Löhle M; Herting B; Schwanebeck U; Oehme L; van den Hoff J; Perick M; Grählert X; Kotzerke J; Reichmann H
    Neurology; 2013 May; 80(19):1754-61. PubMed ID: 23576623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Updates in practical neurology--I. The principles of modern levodopa therapy in Parkinson's disease].
    Klivényi P; Vécsei L
    Ideggyogy Sz; 2007 Jan; 60(1-2):61-4. PubMed ID: 17432097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine agonists and Parkinson's disease progression: what can we learn from neuroimaging studies.
    Marek K; Jennings D; Seibyl J
    Ann Neurol; 2003; 53 Suppl 3():S160-6; discussion S166-9. PubMed ID: 12666107
    [No Abstract]   [Full Text] [Related]  

  • 17. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.
    Whone AL; Watts RL; Stoessl AJ; Davis M; Reske S; Nahmias C; Lang AE; Rascol O; Ribeiro MJ; Remy P; Poewe WH; Hauser RA; Brooks DJ;
    Ann Neurol; 2003 Jul; 54(1):93-101. PubMed ID: 12838524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reevaluation of levodopa therapy for the treatment of advanced Parkinson's disease.
    Yokochi M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S25-30. PubMed ID: 19131038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does treatment with dopamine agonists affect utilization of exogenous levodopa in the parkinsonian striatum?
    Melamed E
    J Neural Transm Suppl; 1995; 45():57-60. PubMed ID: 8748609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the nigrostriatal dopaminergic neurons in mediating the effect of exogenous L-dopa in Parkinson's disease.
    Melamed E
    Mt Sinai J Med; 1988 Jan; 55(1):35-42. PubMed ID: 3279303
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.